WHEN YOUR DENTAL SURGERY REQUIRES BONE GRAFTING
An essential component of any bone healing procedure is the selection of a bone graft for your given procedure, and there are several options to explore. It's important to understand how the recommended bone graft works, the surgical procedure and any risks involved, and what to consider when selecting the right type of bone graft for your situation.
Here are key questions to ask your dentist or oral surgeon.
Why do I need a bone graft (or bone augmentation)?
- What types of bone graft materials are available?
- Are there any differences in effectiveness, safety, or possible side effects among the different materials and the recommended bone grafting procedure?
- Is an autograft replacement an option for me?
- What are the potential complications?
Please describe the procedure to me.
- What exactly happens during this surgery?
- Will the procedure be done in the office or in the hospital?
- Who performs the procedure? What types of dental professionals will be part of my treatment team?
- What are the pros and cons of this dental surgery?
- How large will my incision be and where will it be made? Will I have a scar, and if so, where?
- Is there an alternative procedure that could be done?
- Why do you recommend this procedure to me?
What medications will be prescribed?
- Do they have any side effects?
- Here is a list of all the medications, vitamins and supplements that I currently take. (Make this list ahead of time, and bring in the bottles if you are not sure of the names or dosages.)
- Are there any possible interactions with the new medications you intend to prescribe me? (Include product names, amount of drug per dose, times taken per day, and the prescribing doctor.)
How long will my entire course of treatment take?
- What is the overall treatment plan, and what are my options?
- How often will I need to see you after my dental surgery?
- Will I need to see any other doctors?
- What lifestyle changes, if any, will I need to make?
- When can I return to work and/or resume my normal activities?
Who should I call in your office if I have more questions?
- Are there any materials I can review or websites I can go to and learn more about this dental procedure?
▪In an experimental rabbit study, rhBMP-2 has been shown to elicit antibodies that are capable of crossing the placenta. Reduced ossification of the frontal and parietal bones of the skull was noted infrequently (<3%) in fetuses of rabbit dams immunized to rhBMP-2; however, there was no effect noted in limb bud development. There are no adequate and well-controlled studies in human pregnant women. Women of child bearing potential should be warned by their surgeon of potential risk to a fetus and informed of other possible orthopedic treatments.
▪Women of childbearing potential should be advised that antibody formation to rhBMP-2 or its influence on fetal development has not been completely assessed. In the clinical trial supporting the safety and effectiveness of the Infuse™ Bone Graft/LT-Cage™ Lumbar Tapered Fusion Device, 2/277 (0.7%) patients treated with Infuse™ Bone Graft component and 1/127 (0.8%) patients treated with autograft bone developed antibodies to rhBMP-2. The effect of maternal antibodies to rhBMP-2, as might be present for several months following device implantation, on the unborn fetus is unknown. Additionally, it is unknown whether fetal expression of BMP-2 could re-expose mothers who were previously antibody positive. Theoretically, re-exposure may elicit a more powerful immune response to BMP-2 with possible adverse consequences for the fetus. However, pregnancy did not lead to an increase in antibodies in the rabbit study. Studies in genetically altered mice indicate that BMP-2 is critical to fetal development and that a lack of BMP-2 activity may cause neonatal death or birth defects. It is not known if anti-BMP-2 antibodies may affect fetal development or the extent to which these antibodies may reduce BMP-2 activity.
▪Infuse™ Bone Graft should not be used immediately prior to or during pregnancy. Women of childbearing potential should be advised not to become pregnant for one year following treatment with the Infuse™ Bone Graft/Medtronic Interbody Fusion Device.
▪The safety and effectiveness of the Infuse™ Bone Graft/Medtronic Interbody Fusion Device in nursing mothers has not been established. It is not known if BMP-2 is excreted in human milk.
BRIEF SUMMARY OF INDICATIONS, CONTRAINDICATIONS, WARNINGS, AND PRECAUTION FOR INFUSE BONE GRAFT FOR CERTAIN ORAL MAXILLOFACIAL AND DENTAL REGENERATIVE USES
INFUSE® Bone Graft is indicated as an alternative to autogenous bone graft for sinus augmentations, and for localized alveolar ridge augmentations for defects associated with extraction sockets.
The INFUSE® Bone Graft consists of two components-recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) placed on an absorbable collagen sponge (ACS). These components must be used as a system for the prescribed indication. The bone morphogenetic protein solution component must not be used without the carrier/scaffold component or with a carrier/scaffold component different from the one described in the package insert.
INFUSE® Bone Graft is contraindicated for consumers with a known hypersensitivity to recombinant human Bone Morphogenetic Protein-2, bovine Type I collagen or to other components of the formulation and should not be used in the vicinity of a resected or extant tumor, in consumers with any active malignancy or consumers undergoing treatment for a malignancy, in pregnant women, or consumers with an active infection at the operative site.
There are no adequate and well-controlled studies in human pregnant women. In an experimental rabbit study, rhBMP-2 has been shown to elicit antibodies that are capable of crossing the placenta. Women of childbearing potential should be warned by their surgeon of potential risk to a fetus and informed of other possible dental treatments. The safety and effectiveness of this device has not been established in nursing mothers. Women of childbearing potential should be advised to not become pregnant for one year following treatment with this device.
INFUSE® Bone Graft has not been studied in consumers who are skeletally immature (<18 years of age or no radiographic evidence of epiphyseal closure).
Please see the package insert for the complete list of indications, warnings, precautions, adverse events, clinical results, and other important medical information.